Upgrade to SI Premium - Free Trial

Cytokinetics (CYTK) PT Raised to $110 at Barclays

August 13, 2026 6:15 AM
Barclays analyst Hang Hu raised the price target on Cytokinetics (NASDAQ: CYTK) to $110.00 (from $95.00) while maintaining a Overweight ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change